Elisa Gobbini1, Monia Ezzalfani2, Véronique Dieras3, Thomas Bachelot4, Etienne Brain3, Marc Debled5, William Jacot6, Marie Ange Mouret-Reynier7, Anthony Goncalves8, Florence Dalenc9, Anne Patsouris10, Jean Marc Ferrero11, Christelle Levy12, Veronique Lorgis13, Laurence Vanlemmens14, Claudia Lefeuvre-Plesse15, Simone Mathoulin-Pelissier16, Thierry Petit17, Lionel Uwer18, Christelle Jouannaud19, Marianne Leheurteur20, Magali Lacroix-Triki21, Audrey Lardy Cleaud2, Mathieu Robain22, Coralie Courtinard22, Christian Cailliot22, David Perol2, Suzette Delaloge23. 1. Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France. 2. Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France. 3. Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005 Paris & Saint-Cloud, France. 4. Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France. 5. Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000 Bordeaux, France. 6. Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France. 7. Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France. 8. Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France. 9. Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France. 10. Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue André Boquel, 49055 Angers, France. 11. Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France. 12. Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France. 13. Department of Medical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079 Dijon, France. 14. Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France. 15. Medical Oncology Department, Centre Eugéne Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France. 16. INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, F-33000 Bordeaux, France. 17. Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France. 18. Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France. 19. Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France. 20. Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France. 21. Department of BioPathology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France. 22. Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France. 23. Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.
Abstract
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts. RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively). CONCLUSIONS: The OS of MBC patients has slightly improved over the past decade. However, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBCpatients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts. RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively). CONCLUSIONS: The OS of MBCpatients has slightly improved over the past decade. However, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.
Authors: Inna Y Gong; Andrew T Yan; Craig C Earle; Maureen E Trudeau; Andrea Eisen; Kelvin K W Chan Journal: Breast Cancer Res Treat Date: 2020-03-31 Impact factor: 4.872
Authors: Paul Peter Schneider; Bram L Ramaekers; Xavier Pouwels; Sandra Geurts; Khava Ibragimova; Maaike de Boer; Birgit Vriens; Yes van de Wouw; Marien den Boer; Manon Pepels; Vivianne Tjan-Heijnen; Manuela Joore Journal: Value Health Date: 2021-02-13 Impact factor: 5.725